It is the policy of the Drexel University College of Medicine, Department of Medicine to insure balance, independence, objectivity and scientific rigor in all its sponsored educational programs.  All faculty are expected to disclose to the program audience the approved or investigational status of all generic drugs or products under discussion and any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the program.  This pertains to relationships with pharmaceutical companies, biomedical device manufacturers or other corporations whose products or services are related to the subject matter of the presentation topic.  The intent of this policy is not to prevent faculty with a potential conflict of interest from making a presentation; it is intended that any conflict should be identified openly.